Evidence map›Paper›PMID 30632265›Full record

ArticleJournal of thrombosis and haemostasis : JTH2019

miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway.

Indranil Basak, Seema Bhatlekar, Bhanu K Manne, Micelle Stoller, Sarah Hugo, X Kong, L Ma, Matthew T Rondina, Andrew S Weyrich, Leonard C Edelstein and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Indranil BasakMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-5009-2845
Seema BhatlekarMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
Bhanu K ManneMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-6848-4484
Micelle StollerMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
Sarah HugoMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
X KongThe Cardeza Foundation for Hematologic Research and the Department of Medicine, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA, USA.
L MaThe Cardeza Foundation for Hematologic Research and the Department of Medicine, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA, USA.
Matthew T RondinaMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
Andrew S WeyrichMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
Leonard C EdelsteinThe Cardeza Foundation for Hematologic Research and the Department of Medicine, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA, USA.
Paul F BrayMolecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
University of Utah · USThomas Jefferson University · US

Funding

Translational Control of Megakaryocyte and Platelet Gene Expression in DiseaseR35HL145237 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S · 2019 to 2025
$4.7M
New Therapies to Restore Vascular Integrity During SepsisR01HL130541 · NHLBI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J, WEYRICH, ANDREW S · 2016 to 2020
$3.7M
The Effects of ART on Platelets and HIV-Associated ThrombosisR01HL126547 · NHLBI · UNIVERSITY OF UTAH · PI PLANELLES, VICENTE, RONDINA, MATTHEW THOMAS · 2014 to 2017
$3.0M
In vivo studies of megakaryocyte microRNAs regulating platelet number and integrin activationR01HL141424 · NHLBI · UNIVERSITY OF UTAH · PI BRAY, PAUL F. · 2018 to 2021
$2.5M
Platelet Immune Responses in Aging and InfluenzaR01AG048022 · NIA · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2014 to 2018
$1.8M
MicroRNA function in human megakaryocytesR01HL116713 · NHLBI · UNIVERSITY OF UTAH · PI BRAY, PAUL F. · 2014 to 2017
$1.7M
NHLBI NIH HHS R01 HL116713NHLBI NIH HHS R01 HL126547NHLBI NIH HHS R01 HL130541NHLBI NIH HHS R01 HL141424NHLBI NIH HHS R35 HL145237NIA NIH HHS R01 AG048022
6 · The paper itself

Abstract

Essentials The action of microRNAs (miRs) in human megakaryocyte signaling is largely unknown. Cord blood-derived human megakaryocytes (MKs) were used to test the function of candidate miRs. miR-15a-5p negatively regulated MK GPVI-mediated αIIbβ3 activation and α-granule release. miR-15a-5p acts as a potential "master-miR" regulating genes in the MK GPVI signaling pathway. SUMMARY: Background Megakaryocytes (MKs) invest their progeny platelets with proteins and RNAs. MicroRNAs (miRs), which inhibit mRNA translation into protein, are abundantly expressed in MKs and platelets. Although platelet miRs have been associated with platelet reactivity and disease, there is a paucity of information on the function of miRs in human MKs. Objective To identify MK miRs that regulate the GPVI signaling pathway in the MK-platelet lineage. Methods Candidate miRs associated with GPVI-mediated platelet aggregation were tested for functionality in cultured MKs derived from cord blood. Results An unbiased, transcriptome-wide screen in 154 healthy donors identified platelet miR-15a-5p as significantly negatively associated with CRP-induced platelet aggregation. Platelet agonist dose-response curves demonstrated activation of αIIbβ3 in suspensions of cord blood-derived cultured MKs. Overexpression and knockdown of miR-15a-5p in these MKs reduced and enhanced, respectively, CRP-induced αIIbβ3 activation but did not alter thrombin or ADP stimulation. FYN, SRGN, FCER1G, MYLK. and PRKCQ, genes involved in GPVI signaling, were identified as miR-15a-5p targets and were inhibited or de-repressed in MKs with miR-15a-5p overexpression or inhibition, respectively. Lentiviral overexpression of miR-15a-5p also inhibited GPVI-FcRγ-mediated phosphorylation of Syk and PLCγ2, GPVI downstream signaling molecules, but effects of miR-15a-5p on αIIbβ3 activation did not extend to other ITAM-signaling receptors (FcγRIIa and CLEC-2). Conclusion Cord blood-derived MKs are a useful human system for studying the functional effects of candidate platelet genes. miR-15a-5p is a potential "master-miR" for specifically regulating GPVI-mediated MK-platelet signaling. Targeting miR-15a-5p may have therapeutic potential in hemostasis and thrombosis.

Indexed as

Platelet ActivationSignal TransductionBlood PlateletsCytoplasmic GranulesFetal BloodGene Expression RegulationHCT116 CellsHEK293 CellsHumansMegakaryocytesMicroRNAsPlatelet AggregationPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Membrane GlycoproteinsMicroRNAsMIRN15 microRNA, humanPlatelet Glycoprotein GPIIb-IIIa ComplexPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIGPVIintegrin activationmegakaryocytesmicroRNAsplatelets

Identifiers

PMID30632265
PMCPMC6397079
OpenAlexW2911109829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.